Literature DB >> 18356560

Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension.

Paul R Forfia1, Stephen C Mathai, Micah R Fisher, Traci Housten-Harris, Anna R Hemnes, Hunter C Champion, Reda E Girgis, Paul M Hassoun.   

Abstract

RATIONALE: Hyponatremia is associated with decompensated heart failure and poor prognosis in patients with left ventricular systolic dysfunction.
OBJECTIVES: We sought to determine if hyponatremia is associated with right heart failure and worse prognosis in patients with pulmonary arterial hypertension (PAH).
METHODS: We prospectively followed 40 patients with PAH and examined the relationship between serum sodium and right heart function as well as survival.
MEASUREMENTS AND MAIN RESULTS: Subjects with hyponatremia (Na < or = 136 mEq/L) were more symptomatic (11/13 World Health Organization [WHO] class III/IV vs. 12/27 WHO class III/IV; P = 0.02), had more peripheral edema (69 vs. 26%; P = 0.009), and had higher hospitalization rates (85 vs. 41%; P = 0.009) than normonatremic subjects. Hyponatremic subjects had higher right atrial pressure (14 +/- 6 vs. 9 +/- 3 mm Hg; P < 0.001), lower stroke volume index (21 +/- 7 vs. 32 +/- 10 ml/m(2); P < 0.01), larger right ventricular:left ventricular area ratio (1.8 +/- 0.4 vs. 1.3 +/- 0.4; P < 0.001), and lower tricuspid annular plane systolic excursion (1.4 +/- 0.3 vs. 2.0 +/- 0.6 cm; P = 0.001), despite similar mean pulmonary artery pressure (49 +/- 10 vs. 47 +/- 12 mm Hg; P = 0.60). The 1- and 2-year survival estimates were 93% (95% confidence interval [CI], 73-98%) and 85% (95% CI, 65-94%), and 38% (95% CI, 14-63%) and 15% (95% CI, 2-39%) for normonatremic and hyponatremic subjects, respectively (log-rank chi(2) = 25.19, P < 0.001). The unadjusted risk of death (hazard ratio) in hyponatremic compared with normonatremic subjects was 10.16 (95% CI, 3.42-30.10, P < 0.001). Hyponatremia predicted outcome after adjusting for WHO class, diuretic use, as well as right atrial pressure and cardiac index.
CONCLUSIONS: Hyponatremia is strongly associated with right heart failure and poor survival in PAH.

Entities:  

Mesh:

Year:  2008        PMID: 18356560      PMCID: PMC2427057          DOI: 10.1164/rccm.200712-1876OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  24 in total

Review 1.  Pulmonary arterial hypertension.

Authors:  Harrison W Farber; Joseph Loscalzo
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

2.  Hyponatraemia in heart failure: a call for redefinition.

Authors:  Jalal K Ghali
Journal:  Eur Heart J       Date:  2007-04-12       Impact factor: 29.983

Review 3.  Osmotic and nonosmotic control of vasopressin release.

Authors:  R W Schrier; T Berl; R J Anderson
Journal:  Am J Physiol       Date:  1979-04

4.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

Authors:  T B Levine; G S Francis; S R Goldsmith; A B Simon; J N Cohn
Journal:  Am J Cardiol       Date:  1982-05       Impact factor: 2.778

5.  Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.

Authors:  V J Dzau; W S Colucci; N K Hollenberg; G H Williams
Journal:  Circulation       Date:  1981-03       Impact factor: 29.690

6.  Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.

Authors:  W H Lee; M Packer
Journal:  Circulation       Date:  1986-02       Impact factor: 29.690

7.  Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis.

Authors:  L S Lilly; V J Dzau; G H Williams; L Rydstedt; N K Hollenberg
Journal:  J Clin Endocrinol Metab       Date:  1984-11       Impact factor: 5.958

8.  Increased sympathetic nerve activity in pulmonary artery hypertension.

Authors:  Sonia Velez-Roa; Agnieszka Ciarka; Boutaina Najem; Jean-Luc Vachiery; Robert Naeije; Philippe van de Borne
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

9.  Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.

Authors:  Steven M Kawut; Darren B Taichman; Christine L Archer-Chicko; Harold I Palevsky; Stephen E Kimmel
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

10.  Hyponatraemia as a marker for high renin heart failure.

Authors:  T B Levine; J A Franciosa; T Vrobel; J N Cohn
Journal:  Br Heart J       Date:  1982-02
View more
  53 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 3.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 4.  Right ventricular failure: a novel era of targeted therapy.

Authors:  Dipanjan Banerjee; Francois Haddad; Roham T Zamanian; Jayan Nagendran
Journal:  Curr Heart Fail Rep       Date:  2010-12

5.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

Review 6.  Therapy for pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

7.  Therapies for scleroderma-related pulmonary arterial hypertension.

Authors:  Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2009       Impact factor: 3.772

8.  TrACEing angiotensin II type 1 to right ventricular hypertrophy: are the "sartans" a viable course to treating pulmonary arterial hypertension?

Authors:  Daniel Ranayhossaini; Patrick J Pagano
Journal:  Am J Respir Crit Care Med       Date:  2012-10-15       Impact factor: 21.405

9.  Improved survival in limited scleroderma-related pulmonary artery hypertension.

Authors:  Carlo Marini; Bruno Formichi; Carolina Bauleo; Claudio Michelassi; Roberta Pancani; Renato Prediletto; Massimo Miniati; Giosuè Catapano; Simonetta Monti; Francesca Mannucci; Antonio Tavoni; Anna D'Ascanio; Luigi Emilio Pastormerlo; Alberto Giannoni; Carlo Giuntini
Journal:  Intern Emerg Med       Date:  2013-01-30       Impact factor: 3.397

10.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.